Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis.

Cell death & disease·2021
Same author

Addressing challenges to rolling out COVID-19 vaccines in African countries.

The Lancet. Global health·2021
Same author

Zoonotic Tuberculosis - The Changing Landscape.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Lethal zoonotic coronavirus infections of humans - comparative phylogenetics, epidemiology, transmission, and clinical features of coronavirus disease 2019, The Middle East respiratory syndrome and severe acute respiratory syndrome.

Current opinion in pulmonary medicine·2021
Same journal

Expert consensus on case definitions in human loiasis: a Delphi study.

The Lancet. Infectious diseases·2026
Same journal

The Bundibugyo virus disease outbreak: a warning signal for risks to health workers.

The Lancet. Infectious diseases·2026
Same journal

Trials of medical countermeasures to begin in DR Congo.

The Lancet. Infectious diseases·2026
Same journal

Community-based tuberculosis screening with computer-aided detection technology alone and in combination with point-of-care C-reactive protein testing: a paired screen-positive trial.

The Lancet. Infectious diseases·2026
Same journal

Context matters: WHO-recommended tools in combinations validated for community tuberculosis screening.

The Lancet. Infectious diseases·2026
Same journal

Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

The Lancet. Infectious diseases·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)
10:41

A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)

Published on: April 30, 2020

Tuberculosis biomarkers discovery: developments, needs, and challenges.

Robert S Wallis1, Peter Kim, Stewart Cole

  • 1Specialty Care, Pfizer, Groton, CT, USA.

The Lancet. Infectious Diseases
|March 28, 2013
PubMed
Summary
This summary is machine-generated.

Developing accurate tuberculosis biomarkers is crucial for new treatments and vaccines. While challenges remain, research progresses in predicting treatment success and immune responses, focusing on specific Mycobacterium tuberculosis markers.

More Related Videos

Preparation of Mycobacterium tuberculosis Culture Filtrate to Understand TB Pathogenesis
07:32

Preparation of Mycobacterium tuberculosis Culture Filtrate to Understand TB Pathogenesis

Published on: March 28, 2025

Related Experiment Videos

Last Updated: May 12, 2026

A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)
10:41

A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)

Published on: April 30, 2020

Preparation of Mycobacterium tuberculosis Culture Filtrate to Understand TB Pathogenesis
07:32

Preparation of Mycobacterium tuberculosis Culture Filtrate to Understand TB Pathogenesis

Published on: March 28, 2025

Area of Science:

  • Biomedical Science
  • Infectious Disease Research
  • Clinical Trial Development

Background:

  • Biomarkers are essential for advancing tuberculosis (TB) therapeutics and vaccines.
  • Robust biomarkers reflect core pathological processes, capturing intervention effects on clinical outcomes.
  • Research spans predicting treatment efficacy, latent TB reactivation, and vaccine-induced immunity.

Purpose of the Study:

  • To review progress in tuberculosis biomarker development.
  • To highlight challenges and future directions in biomarker qualification.
  • To emphasize the need for well-characterized biobanks for biomarker validation.

Main Methods:

  • Review of existing literature on Mycobacterium tuberculosis and human biomarkers.
  • Focus on research areas including treatment efficacy, latent infection, and vaccine responses.
  • Analysis of the utility of inflammation markers versus specific biomarkers.

Main Results:

  • No new accurate, TB-specific biomarkers have been discovered yet.
  • Substantial progress has been made in certain biomarker research areas.
  • Older, non-specific inflammation markers lack sufficient predictive value for clinical use.

Conclusions:

  • Qualifying biomarkers as clinical surrogates for TB is highly challenging.
  • Non-culture-based biomarker development requires well-characterized biobanks with long-term patient follow-up.
  • Continued efforts are needed to harness resources and meet future challenges in TB biomarker development.